What was Johnson & Johnson's revenue in Q2 2025?

Revenue reached $22.45 billion, beating estimates of $22.1 billion.

Did Johnson & Johnson raise its 2025 guidance?

Yes, the company raised its full-year revenue forecast to $89.5-$90.5 billion and adjusted EPS to $10.05-$10.15.

What drove JNJ's Q2 earnings growth?

Growth was driven by a 12% increase in Tremfya sales and strong performance of cancer drugs like Darzalex.

Johnson & Johnson Q2 Earnings Beat Estimates on Drug Strength

Johnson & Johnson (JNJ) reported second-quarter 2025 results that exceeded analyst expectations, fueled by robust growth in immunology drug Tremfya and oncology blockbusters. Revenue came in at $22.45 billion, with adjusted EPS of $2.82.

Johnson & Johnson (JNJ) reported second-quarter 2025 earnings that beat Wall Street estimates on Wednesday, driven by strong growth from its medicines unit, particularly immunology drug Tremfya and cancer treatments. Revenue reached $22.45 billion, and adjusted earnings per share came in at $2.82.

Key Financial Results

Metric	Q2 2025	Estimates	YoY Change
Revenue	$22.45B	$22.1B	+5.5%
Adjusted EPS	$2.82	$2.70	+8%
Net Income	$5.6B	-	+6%

Highlights from the Report

The company attributed the beat to a 12% sales jump in Tremfya (psoriasis and psoriatic arthritis) and strong performance of cancer drug Darzalex. The medical devices segment also contributed, albeit at a slower pace.

Guidance

J&J raised its full-year 2025 outlook, now expecting revenue between $89.5B and $90.5B, and adjusted EPS between $10.05 and $10.15.

Stock Impact

Shares of JNJ rose 1.2% in morning trading following the announcement, reflecting investor optimism about the pharmaceuticals segment's strength.

What This Means for Investors

The results underscore the strength of J&J's portfolio in immunology and oncology. With raised guidance, the stock may appeal to investors seeking stability in the healthcare sector.